# Enveric Biosciences, Inc.: Form 10-K/A for the period ended Dec 31, 2016

- Company: [Enveric Biosciences, Inc.](/companies/envb.md) (CIK 890821)
- Form: 10-K/A
- Filed: 2017-04-04
- Accepted by EDGAR: Apr 3, 2017, 20:18 ET
- Period: 2016-12-31
- Accession: 0001079974-17-000131
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/890821/000107997417000131/ameri10ka_12312016.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/890821/000107997417000131/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2016-01-01 to 2016-12-31 | $36.1m | us-gaap:Revenues |
| Cost of revenue | 12 months, 2016-01-01 to 2016-12-31 | $29.6m | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2016-01-01 to 2016-12-31 | $6.5m | us-gaap:GrossProfit |
| Research and development | 12 months, 2016-01-01 to 2016-12-31 | $55.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2016-01-01 to 2016-12-31 | −$5.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2016-01-01 to 2016-12-31 | $751.1k | us-gaap:InterestExpense |
| Income tax | 12 months, 2016-01-01 to 2016-12-31 | −$3.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2016-01-01 to 2016-12-31 | −$2.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2016-01-01 to 2016-12-31 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2016-01-01 to 2016-12-31 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2016-01-01 to 2016-12-31 | 13,068,597 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2016-01-01 to 2016-12-31 | −$2.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2016-12-31 | $1.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-12-31 | $10.1m | us-gaap:AssetsCurrent |
| Total assets | at 2016-12-31 | $39.5m | us-gaap:Assets |
| Current liabilities | at 2016-12-31 | $12.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-12-31 | $27.8m | us-gaap:Liabilities |
| Long-term debt | at 2016-12-31 | $405.4k | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-12-31 | $1.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2016-12-31 | $11.7m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/890821/000107997417000131/ameri10ka_12312016.htm

Filed Apr 4, 2017.
Source: SEC EDGAR, the filing index for accession 0001079974-17-000131. Last ingested by Listed: Nov 14, 2026, 20:02 ET. No prices; not investment advice.
